Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

NCT04847232 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04847232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04847232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2021
Completion date
March 7, 2024
Enrollment
2,690 (actual)
Sites
340

Conditions

As the registry lists them; a condition with its own page is linked.

hyperkalemia